“The European approval of Benlysta represents a significant milestone, and we are very pleased to be able to provide physicians an additional therapeutic option for treating appropriate patients with ...

GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the treatment ...

GSK is shifting to specialty growth (HIV, oncology, asthma) with key launches and a deep late-stage pipeline—still ...

Please provide your email address to receive an email when new articles are posted on . Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic ...

Benlysta® is the first medicine specifically developed and approved for lupus and the first lupus therapy approved for lupus nephritis. It was developed by Human Genome Sciences (HGS) in partnership ...

With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. PHILADELPHIA--(BUSINESS WIRE)-- ...

The FINANCIAL — GSK on September 23 announced that it has filed regulatory submissions in the US and Europe for Benlysta (belimumab) for approval as a subcutaneous formulation in patients with active, ...